Allergen-related approaches to immunotherapy

Pharmacology and Therapeutics

Volumn 121, Issue 3, 2009, Pages 273-284

  Rolland, Jennifer M ^a,b   Gardner, Leanne M ^a,b   O'Hehir, Robyn E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Allergen; Allergen immunotherapy; Allergy; Dendritic cells; Regulatory T cells

Indexed keywords

1018 ISS; ABATACEPT; ALLERGEN; AVE 0675; AVE 7279; CORTICOSTEROID; EPITOPE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LATEX; OMALIZUMAB; ORNECIA; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC DISEASE; ANTIGEN RECOGNITION; APOPTOSIS; ASTHMA; CLONAL ANERGY; DENDRITIC CELL; DRUG EFFICACY; ECZEMA; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; PEANUT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHINITIS; SEA FOOD; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; PEPTIDES; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 60849124499     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.11.007     Document Type: Review

References (202)

1. Abramson M.J., Puy R.M., and Weiner J.M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 4 (2003) (CD001186)
2. Agea E., Russano A., Bistoni O., Mannucci R., Nicoletti I., Corazzi L., et al. Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med 202 2 (2005) 295-308
3. Akdis M., and Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119 4 (2007) 780-791
4. Akdis C.A., and Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 103 2 (2001) 131-136
5. Akdis C.A., Akdis M., Blesken T., Wymann D., Alkan S.S., Muller U., et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 98 7 (1996) 1676-1683
6. Akdis C.A., Blesken T., Akdis M., Wuthrich B., and Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 102 1 (1998) 98-106
7. Akdis M., Verhagen J., Taylor A., Karamloo F., Karagiannidis C., Crameri R., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199 11 (2004) 1567-1575
8. Antico A., Pagani M., and Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 61 10 (2006) 1236-1237
9. Ariano R., Panzani R.C., and Mistrello G. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy-preliminary data. Eur Ann Allergy Clin Immunol 37 3 (2005) 103-108
10. Asher M.I., Montefort S., Bjorksten B., Lai C.K., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 368 9537 (2006) 733-743
11. Bagnasco M., Mariani G., Passalacqua G., Motta C., Bartolomei M., Falagiani P., et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 100 1 (1997) 122-129
12. Barnes P.J. Drugs for asthma. Br J Pharmacol 147 Suppl 1 (2006) S297-S303
13. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195 5 (2002) 603-616
14. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 114 3 (2004) 527-530
15. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7 11 (2007) 875-888
16. Bellinghausen I., Metz G., Enk A.H., Christmann S., Knop J., and Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27 5 (1997) 1131-1139
17. Bohle B., Kinaciyan T., Gerstmayr M., Radakovics A., Jahn-Schmid B., and Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 120 3 (2007) 707-713
18. Bonura A., Amoroso S., Locorotondo G., Di Felice G., Tinghino R., Geraci D., et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 126 1 (2001) 32-40
19. Bottcher M.F., Haggstrom P., Bjorksten B., and Jenmalm M.C. Total and allergen-specific immunoglobulin A levels in saliva in relation to the development of allergy in infants up to 2 years of age. Clin Exp Allergy 32 9 (2002) 1293-1298
20. Bousquet J., Lockey R., and Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102 4 Pt 1 (1998) 558-562
21. Bousquet J., Maasch H., Martinot B., Hejjaoui A., Wahl R., and Michel F.B. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 82 3 Pt 1 (1988) 439-446
22. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 161 12 (1998) 7054-7062
23. Burastero S.E., Mistrello G., Falagiani P., Paolucci C., Breda D., Roncarolo D., et al. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Ann Allergy Asthma Immunol 100 4 (2008) 343-350
24. Calamita Z., Saconato H., Pela A.B., and Atallah A.N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane collaboration method. Allergy 61 10 (2006) 1162-1172
25. Calderon M.A., Alves B., Jacobson M., Hurwitz B., Sheikh A., and Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 1 (2007) (CD001936)
26. Canonica G.W., and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111 3 (2003) 437-448 (quiz 449)
27. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., and Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197 4 (2003) 403-411
28. Caramori G., Ito K., and Adcock I.M. Targeting Th2 cells in asthmatic airways. Curr Drug Targets Inflamm Allergy 3 3 (2004) 243-255
29. Carballido J.M., Faith A., Carballido-Perrig N., and Blaser K. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells. Eur J Immunol 27 2 (1997) 515-521
30. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117 1 (2006) 134-140
31. Chapman M.D., Wunschmann S., and Pomes A. Proteases as Th2 adjuvants. Curr Allergy Asthma Rep 7 5 (2007) 363-367
32. Cosmi L., Santarlasci V., Angeli R., Liotta F., Maggi L., Frosali F., et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 36 3 (2006) 261-272
33. Cox L. Advantages and disadvantages of accelerated immunotherapy schedules. J Allergy Clin Immunol 122 2 (2008) 432-434
34. Cox L.S., Linnemann D.L., Nolte H., Weldon D., Finegold I., and Nelson H.S. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 117 5 (2006) 1021-1035
35. Crameri R., Fluckiger S., Daigle I., Kundig T., and Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 62 2 (2007) 197-206
36. Crellin N.K., Garcia R.V., Hadisfar O., Allan S.E., Steiner T.S., and Levings M.K. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 175 12 (2005) 8051-8059
37. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 14 (2006) 1445-1455
38. Creticos P.S., Van Metre T.E., Mardiney M.R., Rosenberg G.L., Norman P.S., and Adkinson Jr. N.F. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 73 1 Pt 1 (1984) 94-104
39. D'Amato G., Liccardi G., Russo M., Saggese M., and D'Amato M. Measurement of serum levels of eosinophil cationic protein to monitor patients with seasonal respiratory allergy induced by Parietaria pollen (treated and untreated with specific immunotherapy). Allergy 51 4 (1996) 245-250
40. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 121 2 (2008) 512-518 (e512)
41. Dao Nguyen X., and Robinson D.S. Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J Allergy Clin Immunol 114 2 (2004) 296-301
42. Des Roches A., Paradis L., Menardo J.L., Bouges S., Daures J.P., and Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99 4 (1997) 450-453
43. Deurloo D.T., van Esch B.C., Hofstra C.L., Nijkamp F.P., and van Oosterhout A.J. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Am J Respir Cell Mol Biol 25 6 (2001) 751-760
44. Dharajiya N., Boldogh I., Cardenas V., and Sur S. Role of pollen NAD(P)H oxidase in allergic inflammation. Curr Opin Allergy Clin Immunol 8 1 (2008) 57-62
45. Drew A.C., Eusebius N.P., Kenins L., de Silva H.D., Suphioglu C., Rolland J.M., et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 173 9 (2004) 5872-5879
46. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 7 (1999) 468-475
47. Durham S.R., Ying S., Varney V.A., Jacobson M.R., Sudderick R.M., Mackay I.S., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 97 6 (1996) 1356-1365
48. Ebo D.G., Bridts C.H., Hagendorens M.M., Aerts N.E., De Clerck L.S., and Stevens W.J. Basophil activation test by flow cytometry: present and future applications in allergology. Cytometry B Clin Cytom 74 4 (2008) 201-210
49. Esquerre M., Tauzin B., Guiraud M., Muller S., Saoudi A., and Valitutti S. Human regulatory T cells inhibit polarization of T helper cells toward antigen-presenting cells via a TGF-beta-dependent mechanism. Proc Natl Acad Sci U S A 105 7 (2008) 2550-2555
50. Eusebius N.P., Papalia L., Suphioglu C., McLellan S.C., Varney M., Rolland J.M., et al. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol 127 3 (2002) 234-244
51. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 12 (2003) 1206-1212
52. Fehervari Z., and Sakaguchi S. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol 16 12 (2004) 1769-1780
53. Ferreira F., Ebner C., Kramer B., Casari G., Briza P., Kungl A.J., et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 12 2 (1998) 231-242
54. Floistrup H., Swartz J., Bergstrom A., Alm J.S., Scheynius A., van Hage M., et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 117 1 (2006) 59-66
55. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 4 (2003) 330-336
56. Francis J.N., Till S.J., and Durham S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 6 (2003) 1255-1261
57. Frew A.J. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. BMJ 307 6909 (1993) 919-923
58. Frew A.J. Sublingual immunotherapy. N Engl J Med 358 21 (2008) 2259-2264
59. Furmonaviciene R., Ghaemmaghami A.M., Boyd S.E., Jones N.S., Bailey K., Willis A.C., et al. The protease allergen Der p 1 cleaves cell surface DC-SIGN and DC-SIGNR: experimental analysis of in silico substrate identification and implications in allergic responses. Clin Exp Allergy 37 2 (2007) 231-242
60. Garcia G., Godot V., and Humbert M. New chemokine targets for asthma therapy. Curr Allergy Asthma Rep 5 2 (2005) 155-160
61. Gardner L.M., O'Hehir R.E., and Rolland J.M. T cell targeted allergen derivatives for improved efficacy and safety of specific immunotherapy for allergic disease. Curr Med Chem - Anti-inflammatory and Anti-Allergy Agents 2 (2003) 351-365
62. Gardner L.M., O'Hehir R.E., and Rolland J.M. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol 133 1 (2004) 1-13
63. Gardner L.M., Spyroglou L., O'Hehir R.E., and Rolland J.M. Increased allergen concentration enhances IFN-gamma production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy 59 12 (2004) 1308-1317
64. Gardner L.M., Thien F.C., Douglass J.A., Rolland J.M., and O'Hehir R.E. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 34 8 (2004) 1209-1219
65. Gerstmayr M., Ilk N., Schabussova I., Jahn-Schmid B., Egelseer E.M., Sleytr U.B., et al. A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J Immunol 179 11 (2007) 7270-7275
66. Gidaro G.B., Marcucci F., Sensi L., Incorvaia C., Frati F., and Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 35 5 (2005) 565-571
67. Gleich G.J., Zimmermann E.M., Henderson L.L., and Yunginger J.W. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 70 4 (1982) 261-271
68. Gough L., Campbell E., Bayley D., Van Heeke G., and Shakib F. Proteolytic activity of the house dust mite allergen Der p 1 enhances allergenicity in a mouse inhalation model. Clin Exp Allergy 33 8 (2003) 1159-1163
69. Green E.A., Choi Y., and Flavell R.A. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16 2 (2002) 183-191
70. Guerra F., Carracedo J., Solana-Lara R., Sanchez-Guijo P., and Ramirez R. TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin Immunol 107 4 (2001) 647-653
71. Gundlach B.R., Wiesmuller K.H., Junt T., Kienle S., Jung G., and Walden P. Determination of T cell epitopes with random peptide libraries. J Immunol Methods 192 1-2 (1996) 149-155
72. Haavik S., Smestad Paulsen B., and Wold J.K. Glycoprotein allergens in pollen of timothy. I. Investigation of carbohydrates extracted from pollen of timothy (Phleum pratense) and purification of a carbohydrate-containing allergen by affinity chromatography on concanavalin A-sepharose. Int Arch Allergy Appl Immunol 78 2 (1985) 197-205
73. Hammad H., de Heer H.J., Soullie T., Angeli V., Trottein F., Hoogsteden H.C., et al. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 164 1 (2004) 263-271
74. Haselden B.M., Kay A.B., and Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189 12 (1999) 1885-1894
75. Hejjaoui A., Dhivert H., Michel F.B., and Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 85 2 (1990) 473-479
76. Higgins J.A., Lamb J.R., Marsh S.G., Tonks S., Hayball J.D., Rosen-Bronson S., et al. Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp. (house dust mite). J Allergy Clin Immunol 90 5 (1992) 749-756
77. Holm J., Gajhede M., Ferreras M., Henriksen A., Ipsen H., Larsen J.N., et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 173 8 (2004) 5258-5267
78. Horner A.A., Nguyen M.D., Ronaghy A., Cinman N., Verbeek S., and Raz E. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 106 2 (2000) 349-356
79. Hsieh K.H., and Ng C.K. Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy. J Allergy Clin Immunol 91 2 (1993) 650-657
80. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 173 11 (2004) 6526-6531
81. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 2 (2002) 926-932
82. Jacobsen L., Niggemann B., Dreborg S., Ferdousi H.A., Halken S., Host A., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62 8 (2007) 943-948
83. Jaffar Z.H., Stanciu L., Pandit A., Lordan J., Holgate S.T., and Roberts K. Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: role for alphabeta, but not gammadelta, T cells. J Immunol 163 11 (1999) 6283-6291
84. James L.K., and Durham S.R. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy 38 7 (2008) 1074-1088
85. Joint Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 120 (2007) S25-85
86. Jutel M., Akdis M., Blaser K., and Akdis C.A. Mechanisms of allergen specific immunotherapy-T-cell tolerance and more. Allergy 61 7 (2006) 796-807
87. Jutel M., Pichler W.J., Skrbic D., Urwyler A., Dahinden C., and Muller U.R. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154 8 (1995) 4187-4194
88. Kabelitz D., Pohl T., and Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 14 7 (1993) 338-339
89. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3 12 (2003) 984-993
90. Kapsenberg M.L., Jansen H.M., Bos J.D., and Wierenga E.A. Role of type 1 and type 2 T helper cells in allergic diseases. Curr Opin Immunol 4 6 (1992) 788-793
91. Karagiannidis C., Akdis M., Holopainen P., Woolley N.J., Hense G., Ruckert B., et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 114 6 (2004) 1425-1433
92. Karlsson M.R., Rugtveit J., and Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 199 12 (2004) 1679-1688
93. Kauppinen J., Zeiler T., Rautiainen J., Rytkonen-Nissinen M., Taivainen A., Mantyjarvi R., et al. Mutant derivatives of the main respiratory allergen of cow are less allergenic than the intact molecule. Clin Exp Allergy 29 7 (1999) 989-996
94. Kay A.B. Allergy and allergic diseases. First of two parts. N Engl J Med 344 1 (2001) 30-37
95. Keane-Myers A.M., Gause W.C., Finkelman F.D., Xhou X.D., and Wills-Karp M. Development of murine allergic asthma is dependent upon B7-2 costimulation. J Immunol 160 2 (1998) 1036-1043
96. Kleine-Tebbe J., Ribel M., and Herold D.A. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61 2 (2006) 181-184
97. Kline J.N. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 4 3 (2007) 283-288
98. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 4 (2004) 249-258
99. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63 3 (2008) 376-378
100. Korematsu S., Tanaka Y., Hosoi S., Koyanagi S., Yokota T., Mikami B., et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J Immunol 165 5 (2000) 2895-2902
101. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 8 (2005) 2263-2271
102. Kubo T., Hatton R.D., Oliver J., Liu X., Elson C.O., and Weaver C.T. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 173 12 (2004) 7249-7258
103. La Grutta S., Arena A., D'Anneo W.R., Gammeri E., Leonardi S., Trimarchi A., et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial. Eur Ann Allergy Clin Immunol 39 2 (2007) 40-44
104. Lamb J.R., Skidmore B.J., Green N., Chiller J.M., and Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 157 5 (1983) 1434-1447
105. Larche M. Peptide immunotherapy for allergic diseases. Allergy 62 3 (2007) 325-331
106. Larche M., Akdis C.A., and Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 10 (2006) 761-771
107. Lerch E., and Muller U.R. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 101 5 (1998) 606-612
108. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113 2 (2004) 297-302
109. Ling E.M., Smith T., Nguyen X.D., Pridgeon C., Dallman M., Arbery J., et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363 9409 (2004) 608-615
110. Lombardi, V., Van Overtvelt, L., Horiot, S., Moussu, H., Chabre, H., Louise, A., et al. (in press). Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific1187 tolerance via the sublingual route. Clin Exp Allergy. [Jul 17, Electronic publication for ahead of print].
111. Lutz M.B., and Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 23 9 (2002) 445-449
112. Magone M.T., Chan C.C., Beck L., Whitcup S.M., and Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 30 7 (2000) 1841-1850
113. Mahnke K., Bedke T., and Enk A.H. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol (2008)
114. Malling H.J., Abreu-Nogueira J., Alvarez-Cuesta E., Bjorksten B., Bousquet J., Caillot D., et al. Local immunotherapy. Allergy 53 10 (1998) 933-944
115. Malling H.J., Lund L., Ipsen H., and Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 16 3 (2006) 162-168
116. Mannering S.I., Morris J.S., Jensen K.P., Purcell A.W., Honeyman M.C., van Endert P.M., et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods 283 1-2 (2003) 173-183
117. Marone G., Rossi F.W., Detoraki A., Granata F., Genovese A., and Spadaro G. Role of superallergens in allergic disorders. Chem Immunol Allergy 93 (2007) 195-213
118. Marsh D.G., Norman P.S., Roebber M., and Lichtenstein L.M. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 68 6 (1981) 449-459
119. Masoli M., Fabian D., Holt S., and Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 5 (2004) 469-478
120. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 2 (2002) 311-323
121. Mills K.H. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol 4 11 (2004) 841-855
122. Mistrello G., Brenna O., Roncarolo D., Zanoni D., Gentili M., and Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 51 1 (1996) 8-15
123. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., and Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61 2 (2006) 151-165
124. Moller C., Dreborg S., Ferdousi H.A., Halken S., Host A., Jacobsen L., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109 2 (2002) 251-256
125. Mollereau B., Blanchard D., Deas O., Dumont C., Metivier D., Bernard A., et al. Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes: T cells manifesting proliferative unresponsiveness are preferentially susceptible to CD95-mediated apoptosis. J Immunol 159 6 (1997) 2668-2677
126. Mori A., Suko M., Nishizaki Y., Kaminuma O., Kobayashi S., Matsuzaki G., et al. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol 7 3 (1995) 449-457
127. Mueller D.L., Jenkins M.K., and Schwartz R.H. An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. J Immunol 142 8 (1989) 2617-2628
128. Muller U., Helbling A., and Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 44 6 (1989) 412-418
129. Murphy K.M., and Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2 12 (2002) 933-944
130. Nasser S.M., Ying S., Meng Q., Kay A.B., and Ewan P.W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 31 12 (2001) 3704-3713
131. Negro J.M., Wheeler A.W., Hernandez J., Youlten L.J., Pascual A., Garcia-Selles F.J., et al. Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed parietaria pollen extract over a period of three years in monosensitive patients. Allergol Immunopathol (Madr) 27 3 (1999) 153-164
132. Nelson H.S. Allergen immunotherapy: where is it now?. J Allergy Clin Immunol 119 4 (2007) 769-779
133. Noon L. Prophylactic inoculation against hayfever. Lancet 1 (1911) 1572-1573
134. O'Garra A., and Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 10 8 (2004) 801-805
135. O'Hehir R.E., Garman R.D., Greenstein J.L., and Lamb J.R. The specificity and regulation of T-cell responsiveness to allergens. Annu Rev Immunol 9 (1991) 67-95
136. O'Hehir R.E., Yssel H., Verma S., de Vries J.E., Spits H., and Lamb J.R. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol 3 8 (1991) 819-826
137. O'Hehir R.E., Askonas B.A., and Lamb J.R. Cell culture: lymphocyte clones Vol. 3 (1993), Springer-Verlag, Heidelberg
138. O'Hehir R.E., Hoyne G.F., Thomas W.R., and Lamb J.R. House dust mite allergy: from T-cell epitopes to immunotherapy. Eur J Clin Invest 23 12 (1993) 763-772
139. O'Hehir R.E., Sandrini A., Anderson G.P., and Rolland J.M. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem 14 21 (2007) 2235-2244
140. Okada T., Swoboda I., Bhalla P.L., Toriyama K., and Singh M.B. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett 434 3 (1998) 255-260
141. Oldfield W.L., Larche M., and Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360 9326 (2002) 47-53
142. Olsson S., van Hage-Hamsten M., and Whitley P. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol Immunol 35 16 (1998) 1017-1023
143. Pandiyan P., Zheng L., Ishihara S., Reed J., and Lenardo M.J. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8 12 (2007) 1353-1362
144. Passalacqua G., Albano M., Fregonese L., Riccio A., Pronzato C., Mela G.S., et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351 9103 (1998) 629-632
145. Passalacqua G., Guerra L., Compalati E., and Canonica G.W. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2 2 (2007) 117-123
146. Patel P., and Salapatek A.M. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 5 5 (2006) 617-629
147. Pereira-Santos M.C., Baptista A.P., Melo A., Alves R.R., Soares R.S., Pedro E., et al. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 38 2 (2008) 291-297
148. Pilette C., Nouri-Aria K.T., Jacobson M.R., Wilcock L.K., Detry B., Walker S.M., et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 178 7 (2007) 4658-4666
149. Puggioni F., Durham S.R., and Francis J.N. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60 5 (2005) 678-684
150. Purello-D'Ambrosio F., Gangemi S., Merendino R.A., Isola S., Puccinelli P., Parmiani S., et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31 8 (2001) 1295-1302
151. Rabjohn P., West C.M., Connaughton C., Sampson H.A., Helm R.M., Burks A.W., et al. Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation. Int Arch Allergy Immunol 128 1 (2002) 15-23
152. Renz H. Usefulness of mycobacteria in redirecting the immune response in atopic disease. Clin Exp Allergy 34 2 (2004) 167-169
153. Rienzo V.D., Minelli M., Musarra A., Sambugaro R., Pecora S., Canonica W.G., et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 35 5 (2005) 560-564
154. Rolland J., and O'Hehir R. Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr Opin Immunol 10 6 (1998) 640-645
155. Rolland J.M., and O'Hehir R.E. Latex allergy: a model for therapy. Clin Exp Allergy 38 6 (2008) 898-912
156. Rolland J.M., Douglass J., and O'Hehir R.E. Allergen immunotherapy: current and new therapeutic strategies. Expert Opin Investig Drugs 9 3 (2000) 515-527
157. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 12 (1994) 227-257
158. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 5 (2000) 455-458
159. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212 (2006) 8-27
160. Scheffold A., Huhn J., and Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 35 5 (2005) 1336-1341
161. Schramm G., Kahlert H., Suck R., Weber B., Stuwe H.T., Muller W.D., et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 162 4 (1999) 2406-2414
162. Schulze J., Rose M., and Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 62 8 (2007) 963-964
163. Shakib F., Schulz O., and Sewell H. A mite subversive: cleavage of CD23 and CD25 by Der p 1 enhances allergenicity. Immunol Today 19 7 (1998) 313-316
164. Shirakawa T., Enomoto T., Shimazu S., and Hopkin J.M. The inverse association between tuberculin responses and atopic disorder. Science 275 5296 (1997) 77-79
165. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 12 (2001) 1236-1237
166. Singh M.B., de Weerd N., and Bhalla P.L. Genetically engineered plant allergens with reduced anaphylactic activity. Int Arch Allergy Immunol 119 2 (1999) 75-85
167. Smith A.M., Chapman M.D., Taketomi E.A., Platts-Mills T.A., and Sung S.S. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J Allergy Clin Immunol 101 3 (1998) 423-425
168. Soriano Gomis V., Gonzalez Delgado P., and Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 18 3 (2008) 225-226
169. Spangfort M.D. Engineering and validation of recombinant proteins for allergen vaccines. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 94 (2003) 151-154
170. Sparbier K., and Walden P. T cell receptor specificity and mimotopes. Curr Opin Immunol 11 2 (1999) 214-218
171. Spiewak R., Krysinska-Traczyk E., Sitkowska J., and Dutkiewicz J. Microflora of allergenic pollens - a preliminary Study. Ann Agric Environ Med 3 2 (1996) 127-130
172. Stewart G.A., and Robinson C. The immunobiology of allergenic peptidases. Clin Exp Allergy 33 1 (2003) 3-6
173. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., and Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172 3 (2004) 1777-1785
174. Swoboda I., De Weerd N., Bhalla P.L., Niederberger V., Sperr W.R., Valent P., et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 32 1 (2002) 270-280
175. Tang Q., and Bluestone J.A. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship?. Nat Immunol 7 6 (2006) 551-553
176. Tang Q., and Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9 3 (2008) 239-244
177. Thunberg S., Akdis M., Akdis C.A., Gronneberg R., Malmstrom V., Trollmo C., et al. Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy 37 8 (2007) 1127-1136
178. Traidl-Hoffmann C., Mariani V., Hochrein H., Karg K., Wagner H., Ring J., et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 201 4 (2005) 627-636
179. Tsuyuki S., Tsuyuki J., Einsle K., Kopf M., and Coyle A.J. Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J Exp Med 185 9 (1997) 1671-1679
180. Turcanu V., Maleki S.J., and Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J Clin Invest 111 7 (2003) 1065-1072
181. Valenta R., and Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 119 4 (2007) 826-830
182. van der Heijden F.L., Joost van Neerven R.J., van Katwijk M., Bos J.D., and Kapsenberg M.L. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 150 8 Pt 1 (1993) 3643-3650
183. van Neerven R.J., Wikborg T., Lund G., Jacobsen B., Brinch-Nielsen A., Arnved J., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163 5 (1999) 2944-2952
184. Varney V.A., Gaga M., Frew A.J., Aber V.R., Kay A.B., and Durham S.R. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302 6771 (1991) 265-269
185. Varney V.A., Hamid Q.A., Gaga M., Ying S., Jacobson M., Frew A.J., et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92 2 (1993) 644-651
186. Venkataraman C., Leung S., Salvekar A., Mano H., and Schindler U. Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. J Immunol 162 7 (1999) 4053-4061
187. Verdino P., Barderas R., Villalba M., Westritschnig K., Valenta R., Rodriguez R., et al. Three-dimensional structure of the cross-reactive pollen allergen Che a 3: visualizing cross-reactivity on the molecular surfaces of weed, grass, and tree pollen allergens. J Immunol 180 4 (2008) 2313-2321
188. Vervloet D., Birnbaum J., Laurent P., Hugues B., Fardeau M.F., Massabie-Bouchat Y.P., et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 142 3 (2007) 239-246
189. Vrtala S., Akdis C.A., Budak F., Akdis M., Blaser K., Kraft D., et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 165 11 (2000) 6653-6659
190. Vrtala S., Hirtenlehner K., Susani M., Hufnagl P., Binder B.R., Vangelista L., et al. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol 118 2-4 (1999) 218-219
191. Wachholz P.A., and Durham S.R. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 33 9 (2003) 1171-1174
192. Walker S.M., Pajno G.B., Lima M.T., Wilson D.R., and Durham S.R. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 107 1 (2001) 87-93
193. Walunas T.L., Bakker C.Y., and Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183 6 (1996) 2541-2550
194. Wang C.C., and Rook G.A. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 93 3 (1998) 307-313
195. Warner J.O., Price J.F., Soothill J.F., and Hey E.N. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2 8096 (1978) 912-915
196. Watanabe T., Masuyama J., Sohma Y., Inazawa H., Horie K., Kojima K., et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 120 3 (2006) 247-259
197. Wilson D.R., Lima M.T., and Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 1 (2005) 4-12
198. Yagami T., Osuna H., Kouno M., Haishima Y., Nakamura A., and Ikezawa Z. Significance of carbohydrate epitopes in a latex allergen with beta-1,3-glucanase activity. Int Arch Allergy Immunol 129 1 (2002) 27-37
199. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198 2 (2003) 235-247
200. Yazi D., Akkoc T., Yesil O., Ozdemir C., Aydogan M., Koksalan K., et al. Treatment with Mycobacterium vaccae ameliorates airway histopathology in a murine model of asthma. Allergy Asthma Proc 29 1 (2008) 67-73
201. Zeiler T., Taivainen A., Rytkonen M., Rautiainen J., Karjalainen H., Mantyjarvi R., et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 100 6 Pt 1 (1997) 721-727
202. Zuany-Amorim C., Sawicka E., Manlius C., Le Moine A., Brunet L.R., Kemeny D.M., et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 8 6 (2002) 625-629